Overview of JAK Inhibitor Inhaled Formulation
Time: 11:15 am
day: Day One
Details:
- Cataloguing autoimmune diseases where JAK inhalation may be sensible
- Considering toxicity and potential for off-target effects with inhaled JAKs
- Evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of
a novel potent pan-JAK inhaled as a dry powder
